Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHealthSpring Crovalimab Prior Auth | OpenPayer
    Ask Trek AI about this page
    ModifiedHealthSpringPolicy RX501.176

    Crovalimab-akkz

    Customize your policy alerts

    Sign up for healthspring Policy RX501.176 alerts

    Get alerted when Policy RX501.176 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage considerations for crovalimab-akkz and applies to HealthSpring members and their providers. Coverage is subject to the member’s benefit plan or contract, applicable state regulations, and the clinical requirements in the full policy.

    Policy Summary
    PayerHealthSpring
    PolicyCrovalimab-akkz
    Policy CodePolicy RX501.176
    Change TypeModified
    Effective DateMay 7, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization documentation confirming the individual is at least 13 years old, weighs at least 40 kg, has PNH confirmed by specified flow cytometry, and will not receive another PNH biologic concurrently.
    SourceLink
    POLICY UPDATE CHANGES

    A new medical document establishes coverage criteria for crovalimab-akkz (Piasky) in individuals with PNH who are at least 13 years old and weigh at least 40 kg.

    13 yearsMinimum age for medically necessary use
    ≥40 kgMinimum body weight for medically necessary use
    2Permitted flow-cytometry diagnostic pathways
    Piasky REMSRestricted safety program

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Not covered
    Non-FDA-approved indications
    J1307HCPCS code listed

    Coverage Criteria

    Ohio statutory off-label coverage exception

    For Ohio members, coverage of an FDA-approved drug prescribed for an off-label use requires that the use be recognized as safe and effective under the following conditions.

    Ohio statutory exception

    • Recognized evidence source

      • Standard medical reference compendium: The indication is recognized as safe and effective in one or more standard medical reference compendia adopted by the U.S. Department of Health and Human Services.
      • Qualifying medical literature: Safety and efficacy for the proposed off-label use are confirmed in articles from major peer-reviewed professional medical journals presenting data supporting the use as generally safe and effective.2 articles

        Evidence limited to case studies or case series is insufficient. Examples of accepted journals include JAMA, NEJM, and Lancet.

    • Coverage limitations: The FDA has not recognized the requested use as contraindicated, and the drug is not non-formulary.

    Medically necessary PNH treatment

    Covered when all of the following are met.

    Covered PNH treatment

    • Member and diagnosis requirements: The individual is 13 years or older, weighs at least 40 kilograms, and has paroxysmal nocturnal hemoglobinuria.Age ≥13 years; weight ≥40 kg
    • Required PNH diagnostic documentation

      • Flow cytometry of erythrocytes demonstrates CD59 deficiency.
      • Flow cytometry of granulocytes demonstrates CD59 or CD55 deficiency.
    • No concurrent PNH biologic therapy: The individual will not receive crovalimab-akkz concurrently with another biologic used to treat PNH, such as ravulizumab or eculizumab.

    Initial therapy for PNH

    Crovalimab-akkz (Piasky) may be considered medically necessary to reduce hemolysis when all of the following are met.

    Initial therapy eligibility

    • Flow-cytometry confirmation of PNH

      • Flow cytometry of erythrocytes demonstrates CD59 deficiency.
      • Flow cytometry of granulocytes demonstrates CD59 or CD55 deficiency.
    • No concurrent PNH biologic therapy: The individual will not receive crovalimab-akkz concurrently with another biologic used to treat PNH, such as ravulizumab or eculizumab.

    Experimental or unproven use

    Crovalimab-akkz (Piasky) is considered experimental, investigational, and/or unproven for all other indications.

    Non-FDA-approved indication: The requested use is for an indication other than an FDA-approved indication for crovalimab-akkz (Piasky).Not an FDA-approved indication

    Such use is considered experimental, investigational, and/or unproven.

    Coverage is not required when the FDA has recognized the requested use as contraindicated or when crovalimab-akkz is non-formulary.

    The member’s benefit plan, Summary Plan Description, or contract governs if it conflicts with this Medical Policy. These documents may establish applicable exclusions, limitations, dollar caps, duration caps, or other conditions of coverage.

    Crovalimab-akkz (Piasky) is considered experimental, investigational, and/or unproven for indications other than those approved by the U.S. Food and Drug Administration.

    Coverage excludes concurrent treatment with other biologics used to treat PNH, including ravulizumab or eculizumab.

    Coding and Clinical Thresholds

    HCPCS CodesHCPCS
    J1307
    Minimum age
    Minimum age13 years and older
    Covered populationIndividuals with paroxysmal nocturnal hemoglobinuria
    Covered purposeReduction of hemolysis with crovalimab-akkz (Piasky)
    Minimum weight
    Minimum weightAt least 40 kilograms
    Covered populationIndividuals with paroxysmal nocturnal hemoglobinuria
    Covered purposeReduction of hemolysis with crovalimab-akkz (Piasky)

    Provider Documentation and Decision Rules

    Prior Authorization

    Initial Piasky Authorization

    Submit prior authorization documentation showing that the member is 13 years or older, weighs at least 40 kg, has confirmed paroxysmal nocturnal hemoglobinuria (PNH), and meets all applicable covered-use requirements for Piasky to reduce hemolysis.

    • Document age and weight.
    • Document confirmed PNH and applicable clinical criteria.
    • Document that Piasky will not be used concurrently with another biologic for PNH.
    Documentation Required

    Ohio Off-Label Evidence

    For an Ohio member, an FDA-approved drug prescribed for an off-label use may be covered when the use is recognized as safe and effective in an adopted standard compendium or supported by qualifying medical literature. Medical-literature support requires two articles from major peer-reviewed professional medical journals presenting data that support the proposed use as generally safe and effective.

    Policy Background

    This policy addresses coverage of crovalimab-akkz (Piasky) to reduce hemolysis in individuals with paroxysmal nocturnal hemoglobinuria (PNH). Covered use is limited to individuals who are 13 years and older and weigh at least 40 kg, with PNH documented by specified flow-cytometry testing and no concurrent treatment with another biologic used to treat PNH.

    Clinical Definitions

    Paroxysmal nocturnal hemoglobinuria (PNH)
    ConditionA chronic, progressive, debilitating, and life-threatening ultra-rare blood disorder
    Primary disease processComplement-mediated destruction of red blood cells
    Underlying featureDeficient or absent GPI-anchored proteins
    GPI
    Full nameGlycosylphosphatidylinositol
    Cellular roleAn anchor required for certain protective cell-surface proteins
    Related proteinsCD55 and CD59 are GPI-anchored proteins that normally help protect red blood cells from complement-mediated destruction

    Initial Piasky Therapy

    Initial therapy for PNH

    Initial treatment may be considered medically necessary when all of the following are met.

    Initial crovalimab-akkz eligibility

    • Flow-cytometry confirmation of PNH

      • Flow cytometry of erythrocytes demonstrates CD59 deficiency.
      • Flow cytometry of granulocytes demonstrates CD59 or CD55 deficiency.

    Initial Piasky therapy

    Crovalimab-akkz (Piasky) may be considered medically necessary to reduce hemolysis when all requirements are met.

    Initial Piasky therapy eligibility:
    Policy Summary
    PayerHealthSpring
    PolicyCrovalimab-akkz
    Policy CodePolicy RX501.176
    Change TypeModified
    Effective DateMay 7, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization documentation confirming the individual is at least 13 years old, weighs at least 40 kg, has PNH confirmed by specified flow cytometry, and will not receive another PNH biologic concurrently.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Clinical ThresholdsProvider Documentation and Decision RulesPolicy BackgroundClinical DefinitionsInitial Piasky Therapy
    LDH eligibility threshold
    LDH eligibility thresholdAt least 2 times the upper limit of normal
    Additional eligibilityAt least one PNH-related sign or symptom within the past 3 months
    Study populationEligible patients had elevated LDH meeting this threshold
    Hemolysis control
    Hemolysis control thresholdLDH no more than 1.5 times the upper limit of normal
    Assessment periodMean proportion of patients from Week 5 through Week 25
    Measured outcomeHemolysis control
    • Examples of accepted journals include JAMA, NEJM, and Lancet.
    • Accepted evidence may include randomized, double-blind, placebo-controlled clinical trials.
    Documentation Required

    Document PNH by Flow Cytometry

    Document the PNH diagnosis through flow-cytometry analysis demonstrating an acceptable deficiency finding.

    • Flow cytometry of erythrocytes for CD59 deficiency; or
    • Flow cytometry of granulocytes for CD59 or CD55 deficiency.
    Prior Authorization

    Use the Piasky REMS Program

    Piasky is available only through the restricted Piasky Risk Evaluation and Mitigation Strategy (REMS) program. Complete and maintain all applicable REMS requirements before dispensing or administering the drug.

    Documentation Required

    Review Member Benefit Documents

    Apply the written medical policy together with the member’s benefit contract or Summary Plan Description when making a coverage determination.

    • Review defined coverage and non-coverage provisions.
    • Check benefit exclusions and limitations, including dollar or duration caps.
    Documentation Required

    Document Diagnostic Flow-Cytometry Findings

    Retain the laboratory documentation supporting PNH, including the specific flow-cytometry result used to establish the diagnosis.

    • Erythrocyte CD59 deficiency is acceptable.
    • Granulocyte CD59 or CD55 deficiency is acceptable.

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Breakthrough hemolysis
    DefinitionAt least one new or worsening symptom or sign of intravascular hemolysis
    LDH thresholdLDH at least 2 times the upper limit of normal
    Prior control requirementOccurs after LDH was previously reduced to no more than 1.5 times the upper limit of normal on treatment
    Hemoglobin stabilization
    DefinitionAvoidance of a hemoglobin decrease of at least 2 g/dL from baseline
    Hemoglobin thresholdA decrease of at least 2 g/dL from baseline constitutes failure to stabilize hemoglobin
    Transfusion conditionMeasured in the absence of transfusion
    Transfusion avoidance
    DefinitionRemaining free of packed red blood cell transfusion
    Starting pointFrom baseline
    Assessment periodThrough Week 25
    The individual is at least 13 years old, weighs at least 40 kg, has paroxysmal nocturnal hemoglobinuria documented by specified flow cytometry, and will not receive crovalimab-akkz concurrently with another biologic used to treat PNH.
    Age ≥13 years; weight ≥40 kg

    PNH may be documented by CD59 deficiency in erythrocytes or CD59 or CD55 deficiency in granulocytes. Examples of other PNH biologics include ravulizumab and eculizumab.